专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009137871A1 METHODS OF DETECTING CELLS WITH A DISRUPTED CELL MEMBRANE, CELLS INFECTED WITH A PATHOGEN, DYING CELLS OR DEAD CELLS 审中-公开
标题翻译：用破坏性细胞膜检测细胞的方法，用病原体感染的细胞，染色细胞或死亡细胞
公开(公告)号：WO2009137871A1
公开(公告)日：2009-11-19
申请号：PCT/AU2009/000591
申请日：2009-05-01
申请人： WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH , THE BURNET INSTITUTE , LAHOUD, Mireille Hanna , CAMINSCHI, Irina , SHORTMAN, Ken , ZHANG, Jian-Guo , VAN DELFT, Mark Francis , HUANG, David Ching Siang , WRIGHT, Mark Dexter
发明人： LAHOUD, Mireille Hanna , CAMINSCHI, Irina , SHORTMAN, Ken , ZHANG, Jian-Guo , VAN DELFT, Mark Francis , HUANG, David Ching Siang , WRIGHT, Mark Dexter
IPC分类号： A61P37/02 , A61K31/711 , A61P25/28 , A61K31/713 , A61K38/00 , A61P35/00 , A61K39/395
CPC分类号： C07K14/4726 , A61K31/711 , A61K31/713 , C07K16/2851 , C07K2319/02 , C07K2319/43 , C07K2319/90 , G01N33/5308 , G01N2333/705 , G01N2510/00
摘要： The present invention relates to methods of modulating the uptake and/or clearance of cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof, which can be used to treat and/or prevent diseases such as cancer, autoimmunity and infections. The present invention also relates to methods of modulating antigen recognition, processing and/or presentation, as well as immune responses to material derived from cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof. The present invention further relates to methods of detecting cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof.
摘要翻译：本发明涉及调节受破坏的细胞膜，感染病原体的细胞，死亡细胞或死细胞或其部分的细胞的摄取和/或清除的方法，其可用于治疗和/或预防疾病如癌症，自身免疫和感染。本发明还涉及调节抗原识别，加工和/或表达的方法以及对具有破裂的细胞膜的细胞衍生的材料，病原体感染的细胞，死亡细胞或死细胞或其部分的免疫应答。本发明还涉及检测细胞破裂的细胞，病原体感染细胞，染色细胞或死细胞或其一部分的方法。

2. 发明申请

WO2010108215A1 COMPOUNDS AND METHODS FOR MODULATING AN IMMUNE RESPONSE 审中-公开
标题翻译：用于调节免疫应答的化合物和方法
公开(公告)号：WO2010108215A1
公开(公告)日：2010-09-30
申请号：PCT/AU2010/000325
申请日：2010-03-22
申请人： THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH , LAHOUD, Mireille Hanna , CAMINSCHI, Irina , SHORTMAN, Ken , ZHANG, Jian-Guo , VAN DELFT, Mark Francis , HUANG, David Ching Siang , NICOLA, Nicos Anthony , COWMAN, Alan , WRIGHT, Mark Dexter , THE BURNET INSTITUTE
发明人： LAHOUD, Mireille Hanna , CAMINSCHI, Irina , SHORTMAN, Ken , ZHANG, Jian-Guo , VAN DELFT, Mark Francis , HUANG, David Ching Siang , NICOLA, Nicos Anthony , COWMAN, Alan , WRIGHT, Mark Dexter
IPC分类号： A61K38/17 , A61K39/02 , A61K39/12 , A61K39/35 , A61K39/39 , A61K39/395 , A61P35/00 , A61P37/00 , C07K14/435 , C12N5/0784 , C12N15/12
CPC分类号： A61K47/48376 , A61K39/385 , A61K47/64 , A61K47/6801 , A61K2039/505 , A61K2039/6031 , C07K14/47 , C07K16/2851 , C07K2317/24 , C07K2317/34 , C07K2317/622 , C07K2317/626 , G01N33/573 , G01N2333/4724 , G01N2333/9015 , G01N2800/52 , G01N2800/56 , Y02A50/412
摘要： The present invention relates to the identification of proteins which bind the dendritic cell marker known as Clec9A. The present invention provides new compounds for targeting therapeutic agents such as antigens to dendritic cells. Also provided are methods of modulating a humoral and/or T cell mediated immune response to the antigen, methods of delivery of a cytotoxic agent to dendritic cells thereof involved in diseased states, methods of modulating the uptake and/or clearance of cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof, and methods of modulating antigen recognition, processing and/or presentation, as well as immune responses to material derived from cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof.
摘要翻译：本发明涉及结合称为Clec9A的树突细胞标记物的蛋白质的鉴定。本发明提供了用于将治疗剂如抗原靶向树突状细胞的新化合物。还提供了调节对抗原的体液和/或T细胞介导的免疫应答的方法，将细胞毒剂递送至涉及患病状态的树突状细胞的方法，调节受破坏的细胞的摄取和/或清除细胞的方法细胞膜，感染病原体的细胞，死亡细胞或死细胞或其部分，以及调节抗原识别，加工和/或表达的方法以及对具有破裂的细胞膜的细胞衍生的物质的免疫应答，细胞感染病原体，死亡细胞或死细胞，或其一部分。

3. 发明申请

WO2009026660A1 DENDRITIC CELL MARKER AND USES THEREOF 审中-公开
标题翻译： DENDRITIC CELL MARKER及其用途
公开(公告)号：WO2009026660A1
公开(公告)日：2009-03-05
申请号：PCT/AU2008/001294
申请日：2008-08-29
申请人： WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH , THE BURNET INSTITUTE , LAHOUD, Mireille Hanna , PROIETTO, Anna Irene , CAMINSCHI, Irina , SHORTMAN, Ken , LEW, Andrew Mark , WU, Li , WRIGHT, Mark Dexter
发明人： LAHOUD, Mireille Hanna , PROIETTO, Anna Irene , CAMINSCHI, Irina , SHORTMAN, Ken , LEW, Andrew Mark , WU, Li , WRIGHT, Mark Dexter
IPC分类号： C07K16/28 , C12N5/22 , C12N15/09 , G01N33/53
CPC分类号： C07K14/705 , A61K39/385 , A61K39/39 , A61K47/6849 , A61K51/1027 , A61K2039/6056 , C07K14/7056 , C07K16/18 , C07K2317/73 , C12N15/8258 , G01N33/5005 , G01N33/5047 , G01N2333/42 , G01N2333/4724 , G06F19/16 , Y02A50/412
摘要： The present invention relates to the identification of proteins located on the cell surface of dendritic cells or precursors thereof, particularly antigen presenting dendritic cells. In particular, the present invention relates to compounds such as antibodies that bind these proteins. These compounds can be used to detect and/or enrich a subset of dendritic cells or precursors thereof. These compounds can also be used to target antigens to dendritic cells or precursors thereof to modulate a humoral and/or T cell mediated immune response to an antigen, or used to target cytotoxic agents to dendritic cells or precursors thereof involved in diseased states.
摘要翻译：本发明涉及鉴定位于树突状细胞或其前体的细胞表面上的蛋白质，特别是抗原呈递树突状细胞。特别地，本发明涉及化合物，例如结合这些蛋白质的抗体。这些化合物可用于检测和/或富集树突状细胞或其前体的子集。这些化合物也可用于将抗原靶向树突状细胞或其前体，以调节对抗原的体液和/或T细胞介导的免疫应答，或用于将细胞毒剂靶向涉及患病状态的树突状细胞或其前体。

4. 发明申请

WO2014205491A1 BIOLOGICAL MOLECULES AND METHODS OF USE 审中-公开
标题翻译：生物分子和使用方法
公开(公告)号：WO2014205491A1
公开(公告)日：2014-12-31
申请号：PCT/AU2014/000662
申请日：2014-06-25
申请人： MONASH UNIVERSITY , THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH
发明人： NETTER, Hans , CHEONG, Wan-Shoo , KINGSTON, Natalie , CAMINSCHI, Irina , LAHOUD, Mireille
IPC分类号： A61K39/44 , A61K35/76 , A61P31/20 , C07K19/00
CPC分类号： C07K16/2851 , A61K2039/505 , A61K2039/5258 , C07K16/1063 , C07K2317/76 , C07K2319/00 , C07K2319/735
摘要： A recombinant VLP-antibody (VLP-Ab) comprising a modified hepadnaviral envelope fusion protein comprising an antibody variable domain. The variable domain may be selected from an antibody heavy chain variable domain and a light chain variable domain. In some embodiments, the variable domain (the first variable domain) is bound to a complementary antibody variable domain of a second variable domain protein and forms the antibody antigen binding site specific for a target molecule. One second variable domain protein may be a modified hepadnaviral envelope fusion protein comprising a complementary antibody variable domain. The VLP-Ab may comprises a modified hepadnaviral envelope fusion protein comprising a heterologous antigen. One modified hepadnaviral envelope fusion protein is a hepatitis B envelope protein or a VLP-forming part or variant thereof. A eukaryotic expression vector comprising a recombinant nucleic acid molecule encoding a hepadnavirus envelope-antibody fusion protein comprising an antibody variable domain wherein the variable domain is selected from an antibody heavy chain variable domain and a light chain variable domain. A eukaryotic expression vector comprising a recombinant nucleic acid molecule encoding a second variable domain protein comprising an antibody variable domain wherein the variable domain is selected from an antibody heavy chain variable domain and a light chain variable domain. The expression vector may encode a single variable domain selected from an antibody heavy chain variable domain and a light chain variable domain. The expression vector may encode an Sc Fv. A eukaryotic expression vector operably linked to a polynucleotide encoding a hepadnavirus envelope-antibody fusion protein comprising and an antibody variable domain (EAFP) wherein the antibody variable domain is selected from an antibody heavy chain variable domain and a light chain variable domain, and further capable of expressing a second polynucleotide encoding a second variable domain protein comprising a complementary antibody variable domain. An isolated eukaryotic cell comprising the expression vector. Pharmaceutical and diagnostic compositions are provided and a wide range of therapeutic or prophylactic uses and methods. The manufacture of a medicament for, the treatment or prevention of an infection of a subject by a pathogen, or an inflammatory, immunity or cancer-related condition in a subject. A method for preparing a VLP-Ab, the method comprising transfecting a eukaryotic cell with an expression vector as described, culturing the cell in vitro for a time and under conditions sufficient to permit VLP-Ab formation and optionally secretion, and at least partly purifying the VLP-Ab from the cell culture material.
摘要翻译：包含修饰的肝炎病毒包膜融合蛋白的重组VLP-抗体（VLP-Ab），其包含抗体可变结构域。可变结构域可以选自抗体重链可变结构域和轻链可变结构域。在一些实施方案中，可变结构域（第一可变结构域）与第二可变结构域蛋白质的互补抗体可变结构域结合，并形成针对靶分子特异性的抗体抗原结合位点。一秒可变结构域蛋白可以是包含互补抗体可变结构域的修饰的肝炎病毒包膜融合蛋白。 VLP-Ab可以包含包含异源抗原的经修饰的肝炎病毒包膜融合蛋白。一种修饰的肝炎病毒包膜融合蛋白是乙型肝炎包膜蛋白或其形成VLP的部分或变体。包含编码包含抗体可变结构域的肝炎病毒包膜 - 抗体融合蛋白的重组核酸分子的真核表达载体，其中所述可变结构域选自抗体重链可变结构域和轻链可变结构域。包含编码包含抗体可变结构域的第二可变结构域蛋白质的重组核酸分子的真核表达载体，其中所述可变结构域选自抗体重链可变结构域和轻链可变结构域。表达载体可以编码选自抗体重链可变结构域和轻链可变结构域的单个可变结构域。表达载体可以编码Sc Fv。可编码与编码肝炎病毒包膜 - 抗体融合蛋白的多核苷酸可操作地连接的真核表达载体和抗体可变结构域（EAFP），其中抗体可变结构域选自抗体重链可变结构域和轻链可变结构域，表达编码包含互补抗体可变结构域的第二可变结构域蛋白质的第二多核苷酸。包含表达载体的分离的真核细胞。提供药物和诊断组合物以及广泛的治疗或预防用途和方法。在受试者中制造用于治疗或预防受试者受病原体的感染或炎症，免疫或癌症相关病症的药物。一种制备VLP-Ab的方法，所述方法包括用如上所述的表达载体转染真核细胞，在体外培养细胞一段时间并在足以允许VLP-Ab形成和任选分泌的条件下，并至少部分纯化来自细胞培养物质的VLP-Ab。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式